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Abstract
Gabapentin, a relatively new anti-epileptic drug (liED), is emerging as a therapeutic option
JOr treatment refractory and rapid-cycling bipolar illnesses. Pharmacotherapy JOr bipolar disorders
traditionally involves oalproate, carbamazapine, or lithium, drugs which are associated with
numerous adverse effects. Conversely, gabapentin has an attractive pharmacokinetics profile and
relativelyjew side effects. There are no large randomizedcontrolled clinical trials to date examining
gabapentin's role in moodstabilization. However, informal reports have cited encouraging results in
up to 80% ifpatients and general tolerance to side ifJects. Thesefindings make the new drug a
possible choicefor patients who haveJailed to respond to traditional agents or developed sideeffects
which interfere with medication compliance.
METHODOLOGY
A literatu re search of th e Med line and Silver Platter dat ab ases was performed.
English langu age art icles pu blish ed be tween 1990-1997 were reviewed . Keywords
" ga ba pe nt in," " bipola r," "epilepsy," a nd " psychia t ry" were used in va rious combina-
t ions. All articl es whi ch addressed the use of gaba pe ntin in human subj ects were
conside red . Review of citat ions in these articles led to furth er referen ces to th e
clinical use of ga ba pe nt in. All cita tions related to th e use of gaba pentin in th e
t re a tme nt of affec t ive disorders a re included in thi s review. Other art icles which
address clinica lly usefu l ph armacological issu es a re a lso included.
CHEMISTRY
Ga bapentin (Neuro nt in) is a cyclic gamma-amino butyri c ac id (GABA) a nalogue
whi ch may a lter GABA transmiss ion in the centra l nervous syste m (I ). The mol ecul e
incorporates a lipophilic cyclohexa ne rin g into its s t ruc ture, whi ch a llows gabapentin,
un like GABA, to cross th e blood-brain barrier. Pha rmacokinet ic a nd pharmacody-
namic inve st igat ions have la rgely re lied on study of a nimals. The drug was initially
developed as a spas mo lyt ic bu t dem on strat ed e ffec tive a n ticonvulsant properties, and
thus ente red th e ph armaceutica l market as a n AED (2).
Early resea rch in to gabapentin 's mech anism of ac t ion fa iled to provide strong
evide nce of GABAergic ac t ivity. It does not a ppear to sig nificant ly bind to GABA-A,
GABA-B, glu tama te, glycine, or benzodiazapine receptor s; it does not a ffec t volt ag e
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ga te d sod ium or calcium channe ls, a nd it does not eleva te GABA concentra t ion in
nerve terminal s ( 1,3). However, adminis t ra t ion of ga ba pe nt in has been ass ocia te d
with incr eased GABA conce ntra t ion in th e substan t ia nigra , a region rep eated ly
indi cated in th e activity ofGABAergi c anticonvulsants (4) .
Gab ap entin is tran sport ed ac ross e nte ric membran es a nd most likely through
the blood-brain ba rri er a nd into neuron s by a n L-amino ac id carrier (2,5) . It s binding
site has been recently identified as a subunit of a calc ium chann el on neuronal ce ll
sur faces (3,6) . Gab apentin increases th e ra te of synthes is and accumulat ion of GABA,
decr eases th e release of monoamines (do pa m ine, nor epin ephri ne, a nd serotonin),
a nd weakly inhibits GABA-transaminase, an enzyme which degr ad es GABA into
othe r am ino ac ids (3,4).
PHARMACOKINETICS
Gaba pe nt in is becomi ng popula r a mo ng pracu t ione rs du e to its favorabl e
ph a rm acokinetics profil e. It is effic ie nt ly a bsorbed in th e gut following or a l ingestion.
The drug has a hal f-life of 5- 9 hours, rea ch es peak plasm a conce ntrat ion in 2-3 hours,
a nd ac hieves ste ady sta te in 1- 2 days. It is water-soluble an d non-pr ot ei n-bound, bu t
is distributed th rou gh out th e body (includ ing th e CNS) by means of protein trans-
port. Gabap entin is not metabolized , is comple tely elim inated by th e kidneys, a nd
does no t interact wit h hep at ic enzymes. T hese qua liti es theoreti ca lly elim ina te
pot ential interacti ons with other med ica tions (2,5,7) .
CLINICAL USE
Co ntrolled clinical t rials of ga ba pentin in the t reat me nt of psychiatric disorders
have not been performed . Seve ra l anecdotal reports of use exist in th e medi ca l
lit erature (8-12), incl udi ng a growing nu mb er of documents pertaining to gaba pe n-
t in 's ro le in bipo la r illn ess. However, mos t data regarding the drug's efficacy a nd
safety a ppear in rep ort s of ga ba pe ntin's use as a n an t iconvulsan t. T his informa tion
has se rved as a valuabl e guide to pr eliminary stud ies in th e mental health arena .
Three large rand omized cont rolled clin ica l t ria ls have eva luated th e efficacy and
safety of adj unc t ive ga ba pe nt in th erapy in trea ting refractory epilepsy: th e UK
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Gab ap entin Study G roup ( 1990), the US Gab ap ent in Study Group No.5 (1993), and
th e International Gab apentin Study Group (1994) . Drug dosages ranged from 600
mg/d to 1800 mg/d, with th e most effective dosin g regimen reported to be 1800 mg/d.
The percentages of patients in whom se izure fre quency decreased at lea st 50%
(responde rs) we re 25%, 26%, and 28%, resp ect ively ( 19). Morris has since reported a
retrosp ective a nalysis of 100 patients on ga ba pe ntin, 72 of whom experien ced a
greate r th an 50% reducti on in se izu re fre que ncy. The mean drug dos e in this patient
population was 210 7 mg/d; 37 of th e 72 who responded (5 1%) were ta king 1800 mg/d
or less. The remaining patients took 1800-3600 rug/day (20) .
Data regarding th e role of ga ba pe nt in in th e t reat ment of bipolar disorders is
pr eliminary, yet enco uraging . In on e retrosp ecti ve study of bip ola r pa t ien ts who had
fa iled to respond to traditional mood stabilizers or developed intolerable sid e effects
from th ese agents , 92% responded positively to ga ba pe nt in (14) . All other publ ish ed
studies, consist ing of open trials whi ch have included ga ba pe nt in bot h as mono-
th erapy and in addition to other psychotropic medi cation s, have re ported effect ive
improvem ent in th e majority of patients (13,15 ,17,18) . Most patients have d isp layed
noticeable improvem ent in cycling activity with 200-3600 mg/d , th ough doses as low
as 33 mg/d a nd as high as 4900 mg/d ha ve been re por ted ( 13,15). Gabapent in may
also have antidepressant effec ts: patients on th e new AED have noted improvement
in mood , memory attention , ene rgy, slee p, and libido ( 10, 13,17). Elevation in mood
whi ch accompanied th e transition fro m traditional AE Ds to gabapentin, however,
may have resulted from discontinuation of th e sedating side effects of th e tradi tional
agen ts . Further study is need ed to det ermine if ga ba pe nt in has inh e rent antidepres-
sa nt effec ts.
SAFETY
Gab apent in has proven its el f to be a relatively sa fe drug. The most commonly-
encounte red side effec ts a re somnolence (24%), dizzin ess (20%), ataxia (17%), and
fatigu e (14%) (19). Less frequent sid e effor ts include involuntary twitches (1.3%),
rash (0.5%), leukopeni a (0.2%), azo te mia (0.1%), thrombocyto pe nia (0.1%), stutter-
ing (I case), a nd weight ga in (19,21,22). There have been several reported cas es of
hypomania and/or incr eased mood cycling ( 14,15, 17,23) a nd th ere has been on e cas e
of oculogyri c crisis whi ch was emergent ly reversed with a ben zodi azep ine (22).
A th erap eutic range for gaba pe ntin has yet to be es ta blished. Peak steady-state
plasma levels of th e drug ave rage about 4 micrograms/ml (7). There has been one
reported case of overdose, in whi ch a 16-year-old ingest ed 163 capsules (49,900 mg)
without eme sis or return of pill frag me nts on gas tr ic lavage. Her plasma gabapentin
level was 62 micrograms/ml at 8.5 hours afte r ingesti on. She was letha rgic, but was
easily aroused and a ble to converse normall y; by 18 hours post -in gesti on, sh e was alert
and without compla in ts (24) . This case report is cons iste nt wit h a nimal toxicity test s,
in whi ch mice a nd rats experience d only a taxia a nd labored breathing at maximum
dose of 2000 mg/k g IV a nd 8000 mg/k g PO. No ne of the animals expired (24).
Gabapentin has seve ral prop erties whi ch sign ifican tly reduce its pot ential for
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interaction with other drugs. It is non-prot ein-bound, it does not affect hep atic
enzyme ac t ivity, and it has no met ab olites (2) . Alt houg h clinica l trials have not
rep orted any cases of drug-drug interacti on s involving gabapentin (20), a nd some
sources have suggeste d th at such interacti ons are impossibl e (25,26), several report s
have suggested th at th e drug may occas ionally affect or be influenced by othe r
medi cation s.
In on e s tudy, a th erap eutic dos e of a luminum a nd magn esium hydroxide
(Maa lox) , adm inis te re d concom ita ntly with or shortly afte r 400 mg of ga bapentin,
reduced th e bioavail ability of th e latter by 20% (27). C imetidine has reportedly
decr eased the renal clearance of ga ba pe ntin by a cli nica lly significant a mount (7).
There ha s been one case rep ort of ga ba pe nt in interacting with phenytoin . A patient
wit h a long hist ory of complex partial a nd secondarily gen eralized seizures, who was
on three AED 's, began taking ga bapent in. Hi s plasma phenytoin con centration
subseque nt ly incr eased from 42 to 177 mi cro gr amslL a nd returned to baseli ne upon
removal of th e new drug (28). Finally, ga ba pe nt in has been assessed as unlikely to
ca use contraceptive failure when tak en with oral contracept ives (7) .
There a re few reports of pr egn ant wom en ta king gabapentin . No teratogeni c
effects have been not ed in a ny of the 10 reports on file (29). The drug is, however,
fe totoxic in rode nts, associa te d with delayed oss ification, hydrouret er, and hydrone-
phrosis a t doses up to four times greater tha n rela tive standard human dosages (i.e.
3600 mg/d ). There was a lso an incr eased incid en ce of pa ncr eatic acinar cell tumors in
male rats a t high doses, though th ei r life spa n was not a ffec ted by th e neoplasms (30).
Potential uses of ga ba pe nt in in th e pedi at ric affect ive d isorders popu lations have yet
to be determined.
DOSI G
Formal dosin g guide lines a re not ava ilable for th e use of gabapentin in bipol a r
d isord ers. Mainten an ce doses for se izure con trol ra nge fro m 900-2400 mg/d (2,6,19,26)
and pr eli mi nary t rial s of ga bapen tin for mood stabilization seem to suggest a similar
dos e range. The drug's re la t ively sho rt hal f-life necessitat es T ID ad minist ra t ion.
Gabapentin treatment for refractory seizures is gen erally init iat ed with 300 mg once
on the first day, 300 mg twice on the second day and 300 mg three times on th e third
day, with subse que nt incr eases in TID dose as req uired for symptom control (2,19).
O f some clinical significa nce is the fact th at all stu di es to da te exa mining
ga ba pe nt in in th e t reatment of bip ola r illness have inclu ded patients who responded
to a dose less t han 900 mg/d (13-18). In on e study of 28 patient s, th e mean
gabapentin dos e was 539 mg/d ( 15). Hence, increasing dos es by 200 mg inst ead of300
mg may be more appropria te for mood stabi lization.
DISCUSSION
All of th e medi cations presently used to treat bipolar d isor der have significa nt
side effects which impact both qu ality of life and th erapeutic complia nce. Unfortu-
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nately, in this patient population , dissatisfaction wit h trea tment regimen s has th e
pot ential to significa n t ly wor sen th e patient 's clin ica l course by magnifying feelings of
hopelessn ess in a depressed pa t ie nt. Gab apentin holds promise as an adj unc t ive for m
of treatment whi ch has few inherent disadvantages and littl e cha nce of interacting
with ot he r drugs. It s favo ra ble ph armacok inetics profi le is unique a mong mood
stabilize rs . The drug has relat ively few side effects, most of which are beni gn in
natu re. It s possibl e a nt ide pressant effec ts a nd hypoma nic sid e effe cts need fu rther
study. It has thus fa r demonstrated low toxicit y a t the ra pe utic dos es and in overdo se.
Gabape nt in has displ ayed clinical efficacy in up to 80% of bipolar patien ts in
preliminary clinical t rial s, a nd is presently undergoin g invest igation as a possibl e
agent in th e treatment of migr aine headach es, chronic pain, a nd behavioral di sor -
ders. Few reports of ga bape nt in's use in human pr egn ancy exist , and animal studies
ha ve been somewhat dis couragin g.
Current psychi at ric use of ga ba pe nt in is restrict ed to pa tien ts who have fai led to
respond to traditional agents or developed intolerabl e side effects from them. The
upper limit of th e drug' s th erapeutic range mu st be established. Proble ms with
medi cation com plia nce may be improved through th e development of an exte nde d-
re lease or dep ot form of ga ba pe nt in. A large, multi center, randomized, controlled
clinica l trial has ye t to be performed.
CONCLUSIONS
Gab apen tin is a GABA a na logue a nd new AED whi ch has th e unique ability to
cross the blood-brain ba r rier. It appears to influence neuropsychologica l ac tivity by
ac t ing on calcium channels in th e CNS. It has a favorabl e ph armacok inetics profile
an d is proving to be re la t ively sa fe in clinica l pract ice. The drug has displayed both
mood-stabilizing a nd poss ible an ti-de pressant act ivity in pr eliminary tri al s, and is
associated with a relatively beni gn side profile . Further study of thi s new AED is
clearly need ed.
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